Zacks Small Cap Research on MSN
LEXX: DehydraTECH formulation reduces GLP-1 agonist side effects
LEXX READ THE FULL LEXX RESEARCH REPORT Lexaria Bioscience Corporation (NASDAQ:LEXX) announced results from its Phase Ib study evaluating multiple GLP-1 agonists in combination with DehydraTECH (DHT).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback